Experience Utilizing 400 mg Daily of Posaconazole Tablet Formulation in Order to Achieve Desired Minimum Serum Concentrations in Adult Patients with a Hematologic Malignancy or Stem Cell Transplant.
Antimicrob Agents Chemother. 2016 Sep 6;
Authors: Pham AN, Bubalo JS, Lewis JS
We describe our experience using the posaconazole delayed-release tablet formulation 400 mg once daily dosing in 20 hematologic malignancy or hematopoietic stem cell transplant patients who were unable to attain pre-specified target minimum serum (trough) concentrations for invasive fungal infection treatment or prophylaxis. The higher dose allowed the majority of patients to achieve pre-specified target trough concentrations without incurring additional toxicities.
PMID: 27600035 [PubMed - as supplied by publisher]